EIRGENIX INC.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A 2025-11-12 20:47
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A 2025-11-12 16:12
EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives 2023-05-08 10:00
Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar 2021-03-24 23:27
Eirgenix Receives Approval from Japan's PMDA 2020-02-14 15:14
EirGenix, Inc. Enters Into Global License Agreement for the Commercialization of its Biosimilar Drug EG12014 2019-04-30 08:20
1